Dexmedetomidine on Basal Ganglia Neuronal Activity in Parkinson's Disease
Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
The implantation of a deep brain stimulator (DBS) is an established option to improve the
symptoms of Parkinson's disease (PD) in patients that do not respond adequately to medical
therapy. Most centers perform this surgery using a technique that involves microelectrode
recording (MER) of neuronal activity for localization of the target nucleus, microstimulation
of identified targets, and neurological intraoperative testing in a cooperative patient.
Dexmedetomidine, a α2-adrenergic receptors agonist, is a potent anxiolytic that acts at
subcortical areas of the brain without involving GABA receptors. It provides excellent
sedation without respiratory depression; also, it has an analgesic component and a
predictable hemodynamic response. Low maintenance doses do not appear to interfere with MER.
The possible effect of dexmedetomidine in the PD symptoms is still unclear.
Phase:
Phase 4
Details
Lead Sponsor:
Clinica Universidad de Navarra, Universidad de Navarra